Transitioning to Multiple Micronutrient Supplementation: Cost-Effectiveness Analysis
Explore the cost-effectiveness of transitioning from Iron and Folic Acid Supplementation to Multiple Micronutrient Supplementation for maternal health in a specific country. This analysis assesses the health impacts, investment benefits, and budget implications of such a transition based on research and modeling data. Learn about key assumptions and considerations for the transition decision-making process.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
[logo of the institution] Cost-Effectiveness Analysis of Maternal Micronutrient Supplementation in <COUNTRY> <DATE>
Decision? The information in this presentation comes from a tool developed by Nutrition International, accessible at: www.nutritionintl.org/mms-cost-benefit-tool/ Should <COUNTRY> transition from Iron and Folic Acid Supplementation (IFAS) to Multiple Micronutrient Supplementation (MMS) for antenatal programming? The tool is based on research by: Kashi B, Godin CM, Kurzawa, ZA, Verney AMJ, Busch- Hallen, JF, De-Regil, LM. Multiple Micronutrient Supplements are more cost-effective than Iron and Folic Acid: Modeling results from 3 high-burden Asian countries. J Nutrition. 2019 (May). 2
Health Impacts of Transitioning from IFAS to MMS The transition will avert an additional <> Disability Adjusted Life Years (DALY) The transition will prevent the deaths of an additional <> children * Prospective health outcomes over <10> years 3 3
Cost-Effectiveness and Investment Case Benefits of transitioning from IFAS to MMS are <> time greater than the costs The transition can be considered <> according to WHO guidelines (Leech et al., 2018) 4 4 1
Budget Impact of Transitioning Value of DALYs averted <> Additional investment over <10> years <> 5 5
Key Assumptions Population of pregnant women each year - <> Timespan (length of the supplementation program over which costs and benefits are counted) - <> years Coverage: Proportion of pregnant women reached by program - <>% Supplement costs per beneficiary for IFAS and MMS (180 supplements) IFAS - $<> (2016 USD) MMS - $<> (2016 USD) All other costs associated with transition - $<> (2016 USD) Source of assumptions about relative risk of various health outcomes Keats et al. 2019 (Cochrane) or Smith et al. 2017 (Lancet) 6 6
References Kashi B, Godin CM, Kurzawa, ZA, Verney AMJ, Busch-Hallen JF, De-Regil LM. Multiple Micronutrient Supplements are more cost-effective than Iron and Folic Acid: Modeling results from 3 high-burden Asian countries. J Nutrition. 2019;149:1222-1229. Available from: doi.org/10.1093/jn/nxz052 Keats EC, Haider BA, Tam E, Bhutta ZA. Multiple micronutrient supplementation for women during pregnancy. Cochrane Database of Systematic Reviews. 2019: Issue 3. Art. No: CD004905. Available from: DOI:10.1002/14651858.CD004905.pub6. Leech AA, Kim DD, Cohen JT, Neumann PJ. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Tufts Medical Center, 2018; Boston, MA, USA. Available from: doi.org/10.1016/j.jval.2017.12.016. Smith, ER, Shankar AH, Wu LS-F, Said A, Seth A-A, Hasmot A, Rina A et al. Modifiers of the effect of maternal multiple micronutrient supplementation on stillbirth, birth outcomes, and infant mortality: a meta-analysis of individual patient data from 17 randomised trials in low-income and middle-income countries. Lancet Glob. Health. 2017; 5: e1090 e1100. 7 7
